Pharming B.V.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Industrial and Commercial Machinery and Equipment, Not Elsewhere Classified), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Pharming B.V.
Live alerts from global media, monitored by Business Radar
2024-09-27 (iex.nl)
Final call: BAM and Pharming are in great demand on green-colored Damrak
The AEX closed 0.6% higher, good for a weekly gain of 2.2%. And furthermore: PCE inflation, Pharming, BAM, Flow Traders and we are already looking ahead to the coming stock market week.
Read more
2024-09-27 (iex.nl)
Final call: BAM and Pharming are in great demand on green-colored Damrak
The AEX closed 0.6% higher, good for a weekly gain of 2.2%. And furthermore: PCE inflation, Pharming, BAM, Flow Traders and we are already looking ahead to the coming stock market week.
Read more
2024-09-26 (nationalezorggids.nl)
Third market authorization for Joenja from Leids Pharming
The Leiden biotechnology company Pharming has received permission in the United Kingdom to market its second drug. After similar approvals in the United States and Israel, this is the third market authorization for the drug Joenja, which works against a very rare
Read more
2024-09-26 (iex.nl)
British green light for Joenja from Pharming
Pharming has received market approval from the British regulator MHRA for the sale of its drug Joenja for the treatment of APDS, a rare and progressive primary immune system disorder. That made the biopharmaceutical bed...
Read more
2024-05-23 (veb.net)
Pharming sticks to strategy despite frustration about share price
A top executive complaining about the low share price. Are investors so stupid that they do not understand the strategy of biotech company Pharming, is communication faltering, or does the market distrust the great plans?
Read more
2024-01-11 (beleggersbelangen.nl)
Readers Competition | Especially Nasdaq popular for 2024
The annual readers' competition of Beleggers Belangen has once again produced a large number of well-known and lesser-known names for 2024.
Read more
2018-08-24 (telegraaf.nl)
More competition for Pharmings Ruconest | Financial | .nl
The FDA has approved the launch of Shire's Lanadelumab in the US market. This is a new drug against angioedema, in which the Dutch Pharming operates with Ruconest.
Read more